Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1999 Mar;58(3):136–141. doi: 10.1136/ard.58.3.136

Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt?

C Jorgensen 1, F Apparailly 1, J Sany 1
PMCID: PMC1752849  PMID: 10364909

Full Text

The Full Text of this article is available as a PDF (118.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham E., Glauser M. P., Butler T., Garbino J., Gelmont D., Laterre P. F., Kudsk K., Bruining H. A., Otto C., Tobin E. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA. 1997 May 21;277(19):1531–1538. [PubMed] [Google Scholar]
  2. Abraham E., Wunderink R., Silverman H., Perl T. M., Nasraway S., Levy H., Bone R., Wenzel R. P., Balk R., Allred R. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995 Mar 22;273(12):934–941. [PubMed] [Google Scholar]
  3. Akdis C. A., Blesken T., Akdis M., Wüthrich B., Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest. 1998 Jul 1;102(1):98–106. doi: 10.1172/JCI2250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Allavena P., Piemonti L., Longoni D., Bernasconi S., Stoppacciaro A., Ruco L., Mantovani A. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol. 1998 Jan;28(1):359–369. doi: 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  5. Apparailly F., Verwaerde C., Jacquet C., Auriault C., Sany J., Jorgensen C. Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol. 1998 Jun 1;160(11):5213–5220. [PubMed] [Google Scholar]
  6. Arend W. P., Dayer J. M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 1990 Mar;33(3):305–315. doi: 10.1002/art.1780330302. [DOI] [PubMed] [Google Scholar]
  7. Asadullah K., Sterry W., Stephanek K., Jasulaitis D., Leupold M., Audring H., Volk H. D., Döcke W. D. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest. 1998 Feb 15;101(4):783–794. doi: 10.1172/JCI1476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brandtzaeg P., Osnes L., Ovstebø R., Joø G. B., Westvik A. B., Kierulf P. Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes. J Exp Med. 1996 Jul 1;184(1):51–60. doi: 10.1084/jem.184.1.51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Brennan F. M., Maini R. N., Feldmann M. TNF alpha--a pivotal role in rheumatoid arthritis? Br J Rheumatol. 1992 May;31(5):293–298. doi: 10.1093/rheumatology/31.5.293. [DOI] [PubMed] [Google Scholar]
  10. Campion G. V., Lebsack M. E., Lookabaugh J., Gordon G., Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum. 1996 Jul;39(7):1092–1101. doi: 10.1002/art.1780390704. [DOI] [PubMed] [Google Scholar]
  11. Chernoff A. E., Granowitz E. V., Shapiro L., Vannier E., Lonnemann G., Angel J. B., Kennedy J. S., Rabson A. R., Wolff S. M., Dinarello C. A. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol. 1995 May 15;154(10):5492–5499. [PubMed] [Google Scholar]
  12. Drevlow B. E., Lovis R., Haag M. A., Sinacore J. M., Jacobs C., Blosche C., Landay A., Moreland L. W., Pope R. M. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. 1996 Feb;39(2):257–265. doi: 10.1002/art.1780390212. [DOI] [PubMed] [Google Scholar]
  13. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Bijl H., Woody J. N. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1125–1127. doi: 10.1016/s0140-6736(94)90632-7. [DOI] [PubMed] [Google Scholar]
  14. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F. M., Walker J., Bijl H., Ghrayeb J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993 Dec;36(12):1681–1690. doi: 10.1002/art.1780361206. [DOI] [PubMed] [Google Scholar]
  15. Firestein G. S., Boyle D. L., Yu C., Paine M. M., Whisenand T. D., Zvaifler N. J., Arend W. P. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum. 1994 May;37(5):644–652. doi: 10.1002/art.1780370507. [DOI] [PubMed] [Google Scholar]
  16. Fisher C. J., Jr, Dhainaut J. F., Opal S. M., Pribble J. P., Balk R. A., Slotman G. J., Iberti T. J., Rackow E. C., Shapiro M. J., Greenman R. L. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994 Jun 15;271(23):1836–1843. [PubMed] [Google Scholar]
  17. Joosten L. A., Helsen M. M., van de Loo F. A., van den Berg W. B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum. 1996 May;39(5):797–809. doi: 10.1002/art.1780390513. [DOI] [PubMed] [Google Scholar]
  18. Jorgensen C., Apparailly F., Couret I., Canovas F., Jacquet C., Sany J. Interleukin-4 and interleukin-10 are chondroprotective and decrease mononuclear cell recruitment in human rheumatoid synovium in vivo. Immunology. 1998 Apr;93(4):518–523. doi: 10.1046/j.1365-2567.1998.00457.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Jorgensen C., Couret I., Canovas F., Bologna C., Brochier J., Reme T., Lipsky P., Sany J. Mononuclear cell retention in rheumatoid synovial tissue engrafted in severe combined immunodeficient (SCID) mice is up-regulated by tumour necrosis factor-alpha (TNF-alpha) and mediated through intercellular adhesion molecule-1 (ICAM-1). Clin Exp Immunol. 1996 Oct;106(1):20–25. [PubMed] [Google Scholar]
  20. Katsikis P. D., Chu C. Q., Brennan F. M., Maini R. N., Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med. 1994 May 1;179(5):1517–1527. doi: 10.1084/jem.179.5.1517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kawakami A., Eguchi K., Matsuoka N., Tsuboi M., Urayama S., Kawabe Y., Aoyagi T., Maeda K., Nagataki S. Inhibitory effects of interleukin-10 on synovial cells of rheumatoid arthritis. Immunology. 1997 Jun;91(2):252–259. doi: 10.1046/j.1365-2567.1997.00244.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lacraz S., Nicod L. P., Chicheportiche R., Welgus H. G., Dayer J. M. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest. 1995 Nov;96(5):2304–2310. doi: 10.1172/JCI118286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lorenz H. M., Antoni C., Valerius T., Repp R., Grünke M., Schwerdtner N., Nüsslein H., Woody J., Kalden J. R., Manger B. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol. 1996 Feb 15;156(4):1646–1653. [PubMed] [Google Scholar]
  24. Maini R. N., Breedveld F. C., Kalden J. R., Smolen J. S., Davis D., Macfarlane J. D., Antoni C., Leeb B., Elliott M. J., Woody J. N. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998 Sep;41(9):1552–1563. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  25. Maini R. N., Elliott M. J., Brennan F. M., Williams R. O., Chu C. Q., Paleolog E., Charles P. J., Taylor P. C., Feldmann M. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev. 1995 Apr;144:195–223. doi: 10.1111/j.1600-065x.1995.tb00070.x. [DOI] [PubMed] [Google Scholar]
  26. Moreland L. W., Heck L. W., Jr, Koopman W. J. Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum. 1997 Mar;40(3):397–409. doi: 10.1002/art.1780400302. [DOI] [PubMed] [Google Scholar]
  27. Ohshima S., Saeki Y., Mima T., Sasai M., Nishioka K., Nomura S., Kopf M., Katada Y., Tanaka T., Suemura M. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8222–8226. doi: 10.1073/pnas.95.14.8222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Paleolog E. M., Hunt M., Elliott M. J., Feldmann M., Maini R. N., Woody J. N. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum. 1996 Jul;39(7):1082–1091. doi: 10.1002/art.1780390703. [DOI] [PubMed] [Google Scholar]
  29. Satoskar A. R., Okano M., Connaughton S., Raisanen-Sokolwski A., David J. R., Labow M. Enhanced Th2-like responses in IL-1 type 1 receptor-deficient mice. Eur J Immunol. 1998 Jul;28(7):2066–2074. doi: 10.1002/(SICI)1521-4141(199807)28:07<2066::AID-IMMU2066>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  30. Tak P. P., Taylor P. C., Breedveld F. C., Smeets T. J., Daha M. R., Kluin P. M., Meinders A. E., Maini R. N. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1996 Jul;39(7):1077–1081. doi: 10.1002/art.1780390702. [DOI] [PubMed] [Google Scholar]
  31. Walmsley M., Katsikis P. D., Abney E., Parry S., Williams R. O., Maini R. N., Feldmann M. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum. 1996 Mar;39(3):495–503. doi: 10.1002/art.1780390318. [DOI] [PubMed] [Google Scholar]
  32. Walmsley M., Katsikis P. D., Abney E., Parry S., Williams R. O., Maini R. N., Feldmann M. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum. 1996 Mar;39(3):495–503. doi: 10.1002/art.1780390318. [DOI] [PubMed] [Google Scholar]
  33. Weckmann A. L., Alcocer-Varela J. Cytokine inhibitors in autoimmune disease. Semin Arthritis Rheum. 1996 Oct;26(2):539–557. doi: 10.1016/s0049-0172(96)80042-4. [DOI] [PubMed] [Google Scholar]
  34. Wendling D., Racadot E., Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol. 1993 Feb;20(2):259–262. [PubMed] [Google Scholar]
  35. de Waal Malefyt R., Abrams J., Bennett B., Figdor C. G., de Vries J. E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991 Nov 1;174(5):1209–1220. doi: 10.1084/jem.174.5.1209. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES